McGraw-Hill, CME Launch S&P-Dow Jones Index Joint Venture

standard-poors

McGraw-Hill and CME Group today unveiled S&P Dow Jones Indices, a joint venture that combines McGraw-Hill's S&P Indices with CME's Dow Jones Indexes subsidiary.

As reported by Inside Market Data last November, former executive managing director of S&P Indices Alexander Matturi has been appointed chief executive of the joint venture (IMD, Nov. 5, 2011), while S&P Capital IQ president Lou Eccleston is chairman of the board of directors, which also includes Robert Shokotko, managing director of S&P Dow Jones Indices; Charles Teschner, executive vice president of global strategy and corporate development at McGraw-Hill; Elizabeth O'Melia, senior vice president of treasury operations at McGraw-Hill; John Pietrowicz, senior managing director of business development and corporate finance at CME; and Scot Warren, senior managing director of equity index products and index services at CME.

McGraw-Hill holds 73 percent of S&P Dow Jones Indices, while CME and Dow Jones own 24.4 percent and 2.6 percent, respectively, and under the commercial terms of the deal, CME will pay S&P Dow Jones Indices a percentage of any listing, trading and clearing revenues linked to index products operated by the joint venture.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

The Waters Cooler: ’Tis the Season!

Everyone is burned out and tired and wants to just chillax in the warm watching some Securities and Exchange Commission videos on YouTube. No? Just me?

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here